Novo Nordisk (NVO): In 2023, Novo Nordisk announced the results from its SELECT trial that showed that semaglutide was associated with a 20% decreased risk of major adverse cardiac events comprised of cardiovascular death, nonfatal myocardial infarction (MI), and stroke compared with placebo in patients with overweight or obesity and established CVD but without diabetes
Since GLP-1 drugs have come to market, supplement companies have championed nutraceutical solutions for weight management
Independent Wellness emphasizes provider-led care, the same provider throughout treatment, Bonnie Lea Davis, FNP-C, personalized dosing guidance, unlimited provider access, lab support when relevant, transparent pricing, and ongoing maintenance planning
Bacopa ondersteunt de concentratie en het geheugen2 en vitamine B6 draagt bij tot de vermindering van moeheid1